No Data
No Data
Express News | Marizyme Inc - Qualigen Purchased Exclusive Negotiation Period Ending May 31 for Proposing Broader Strategic Relationship Between Two Companies
Express News | Marizyme Inc - Qualigen Will Help Support Commercial Launch in United States of Duragraft
Express News | Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared Duragraft™
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
Express News | Qualigen Therapeutics Highlights Poster Featuring Early Clinical Experience With QN-302 At American Association Of Cancer Research 2024 Annual Meeting
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience With QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. ("Qualigen" or the "Company," Nasdaq: QLGN) today announces that a poster featuring its early clinical experience wit
No Data